These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 20187091)

  • 1. Changes in markers of ovarian reserve and endocrine function in young women with breast cancer undergoing adjuvant chemotherapy.
    Yu B; Douglas N; Ferin MJ; Nakhuda GS; Crew K; Lobo RA; Hershman DL
    Cancer; 2010 May; 116(9):2099-105. PubMed ID: 20187091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of chemotherapy-induced ovarian failure in premenopausal women undergoing chemotherapy for breast cancer.
    Tiong V; Rozita AM; Taib NA; Yip CH; Ng CH
    World J Surg; 2014 Sep; 38(9):2288-96. PubMed ID: 24700093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of ovarian function after chemotherapy in women with early and locally advanced breast cancer from Serbia.
    Malisic E; Susnjar S; Milovanovic J; Todorovic-Rakovic N; Kesic V
    Arch Gynecol Obstet; 2018 Feb; 297(2):495-503. PubMed ID: 29101609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapy-Related Amenorrhea and Menopause in Young Chinese Breast Cancer Patients: Analysis on Incidence, Risk Factors and Serum Hormone Profiles.
    Liem GS; Mo FK; Pang E; Suen JJ; Tang NL; Lee KM; Yip CH; Tam WH; Ng R; Koh J; Yip CC; Kong GW; Yeo W
    PLoS One; 2015; 10(10):e0140842. PubMed ID: 26485568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prechemotherapy antimullerian hormone, age, and body size predict timing of return of ovarian function in young breast cancer patients.
    Su HC; Haunschild C; Chung K; Komrokian S; Boles S; Sammel MD; DeMichele A
    Cancer; 2014 Dec; 120(23):3691-8. PubMed ID: 25081546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protective effect of goserelin on ovarian reserve during (neo)adjuvant chemotherapy in young breast cancer patients: a prospective cohort study in China.
    Wang S; Pei L; Hu T; Jia M; Wang S
    Hum Reprod; 2021 Mar; 36(4):976-986. PubMed ID: 33411897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pretreatment anti-Mullerian hormone-based nomogram predicts menstruation status after chemotherapy for premenopausal women with hormone receptor-positive early breast cancer.
    Xue C; Wei W; Sun P; Zheng W; Diao X; Xu F; Huang J; An X; Xia W; Hong R; Jiang K; Huang R; Yuan Z; Wang S; Li A; Zou R; Shi Y
    Breast Cancer Res Treat; 2019 Feb; 173(3):619-628. PubMed ID: 30392113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pretreatment serum anti-müllerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer.
    Anderson RA; Cameron DA
    J Clin Endocrinol Metab; 2011 May; 96(5):1336-43. PubMed ID: 21325458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pilot study of predictive markers of chemotherapy-related amenorrhea among premenopausal women with early stage breast cancer.
    Anders C; Marcom PK; Peterson B; Gu L; Unruhe S; Welch R; Lyons P; Behera M; Copland S; Kimmick G; Shaw H; Snyder S; Antenos M; Woodruff T; Blackwell K
    Cancer Invest; 2008; 26(3):286-95. PubMed ID: 18317970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antimullerian hormone and inhibin B are hormone measures of ovarian function in late reproductive-aged breast cancer survivors.
    Su HI; Sammel MD; Green J; Velders L; Stankiewicz C; Matro J; Freeman EW; Gracia CR; DeMichele A
    Cancer; 2010 Feb; 116(3):592-9. PubMed ID: 19918920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantifying effect of combined oral contraceptive pill on functional ovarian reserve as measured by serum anti-Müllerian hormone and small antral follicle count using three-dimensional ultrasound.
    Deb S; Campbell BK; Pincott-Allen C; Clewes JS; Cumberpatch G; Raine-Fenning NJ
    Ultrasound Obstet Gynecol; 2012 May; 39(5):574-80. PubMed ID: 21997961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence and Predictive Factors for Recovery of Ovarian Function in Amenorrheic Women in Their 40s Treated With Letrozole.
    Krekow LK; Hellerstedt BA; Collea RP; Papish S; Diggikar SM; Resta R; Vukelja SJ; Holmes FA; Reddy PK; Asmar L; Wang Y; Fox PS; Peck SR; O'Shaughnessy J
    J Clin Oncol; 2016 May; 34(14):1594-600. PubMed ID: 26884554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy-induced ovarian failure in young women with early breast cancer: Prospective analysis of four randomised neoadjuvant/adjuvant breast cancer trials.
    Furlanetto J; Marmé F; Seiler S; Thode C; Untch M; Schmatloch S; Schneeweiss A; Bassy M; Fasching PA; Strik D; Stickeler E; Schem C; Karn T; Grischke EM; Denkert C; van Mackelenbergh M; Müller V; Nekljudova V; Loibl S
    Eur J Cancer; 2021 Jul; 152():193-203. PubMed ID: 34116270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Feature of amenorrhea in postoperative tamoxifen users with breast cancer.
    Kim H; Han W; Ku SY; Suh CS; Kim SH; Choi YM
    J Gynecol Oncol; 2017 Mar; 28(2):e10. PubMed ID: 27894163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association Between Biomarkers of Ovarian Reserve and Infertility Among Older Women of Reproductive Age.
    Steiner AZ; Pritchard D; Stanczyk FZ; Kesner JS; Meadows JW; Herring AH; Baird DD
    JAMA; 2017 Oct; 318(14):1367-1376. PubMed ID: 29049585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum antimüllerian hormone/müllerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol.
    Hazout A; Bouchard P; Seifer DB; Aussage P; Junca AM; Cohen-Bacrie P
    Fertil Steril; 2004 Nov; 82(5):1323-9. PubMed ID: 15533354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-Müllerian hormone (AMH) levels in premenopausal breast cancer patients treated with taxane-based adjuvant chemotherapy - A translational research project of the SUCCESS A study.
    Trapp E; Steidl J; Rack B; Kupka MS; Andergassen U; Jückstock J; Kurt A; Vilsmaier T; de Gregorio A; de Gregorio N; Tzschaschel M; Lato C; Polasik A; Tesch H; Schneeweiss A; Beckmann MW; Fasching PA; Janni W; Müller V
    Breast; 2017 Oct; 35():130-135. PubMed ID: 28732324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-Mullerian hormone: determination of ovarian reserve in early breast cancer patients.
    Bozza C; Puglisi F; Lambertini M; Osa EO; Manno M; Del Mastro L
    Endocr Relat Cancer; 2014 Feb; 21(1):R51-65. PubMed ID: 24292601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endocrine status of premenopausal node-positive breast cancer patients following adjuvant chemotherapy and long-term tamoxifen.
    Ravdin PM; Fritz NF; Tormey DC; Jordan VC
    Cancer Res; 1988 Feb; 48(4):1026-9. PubMed ID: 3123050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced ovarian reserve in young early breast cancer patients: preliminary data from a prospective cohort trial.
    Wenners A; Grambach J; Koss J; Maass N; Jonat W; Schmutzler A; Mundhenke C
    BMC Cancer; 2017 Sep; 17(1):632. PubMed ID: 28877720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.